A peptide targeting outer membrane protein A of Acinetobacter baumannii exhibits antibacterial activity by reducing bacterial pathogenicity
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00565-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Hui Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Bacterial Outer Membrane Proteins, Anti-Bacterial Agents, Biofilms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), | Shaanxi Provincial Key Research and Development Project (Shaanxi Key Research and Development Program), 陕西省科学技术厅 | Shaanxi Provincial Key Research and Development Project.
Abstract (Originalsprache)
The World Health Organization has classified multidrug-resistant (MDR) Acinetobacter baumannii as a significant threat to human health, necessitating the urgent discovery of new antibacterial drugs to combat bacterial resistance. Outer membrane protein A of A. baumannii (AbOmpA) is an outer membrane-anchored β-barrel-shaped pore protein that plays a critical role in bacterial adhesion, invasion, and biofilm formation. Therefore, AbOmpA is considered a key virulence factor of A. baumannii . Herein, we screened three phage display peptide libraries targeting AbOmpA and identified several peptides. Among them, P92 (amino acid sequence: QMGFMTSPKHSV) exhibited the highest binding affinity with AbOmpA, with a KD value of 7.84 nM. In vitro studies demonstrated that although P92 did not directly inhibit bacterial growth, it significantly reduced the invasion and adhesion capabilities of multiple clinical isolates of MDR A. baumannii and concentration-dependently inhibited biofilm formation by acting on OmpA. Furthermore, the polymerase chain reaction results confirmed a significant positive correlation between the antibacterial effect of P92 and OmpA expression levels. Encouragingly, P92 also displayed remarkable therapeutic efficacy against A. baumannii infection in various models, including an in vitro cell infection model, a mouse skin infection model, and a mouse sepsis model. These results highlight P92 as a novel and highly effective antimicrobial molecule specifically targeting the virulence factor AbOmpA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, China.
- Department of Clinical Laboratory, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
ORCID-Profile: Mingkai Li, Xiaoyan Xue
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- | Shaanxi Provincial Key Research and Development Project (Shaanxi Key Research and Development Program)
- 陕西省科学技术厅 | Shaanxi Provincial Key Research and Development Project
Zitieren
APA
Zhao, H., Hu, Y., Nie, D., Li, N., Chen, Z., Zhou, S., Li, M., & Xue, X. (2024). A peptide targeting outer membrane protein A of Acinetobacter baumannii exhibits antibacterial activity by reducing bacterial pathogenicity. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00565-24
Vancouver
Zhao H, Hu Y, Nie D, Li N, Chen Z, Zhou S, et al. A peptide targeting outer membrane protein A of Acinetobacter baumannii exhibits antibacterial activity by reducing bacterial pathogenicity. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00565-24
BibTeX
@article{Zhao2024,
author = {Zhao, Hui and Hu, Yue and Nie, Dan and Li, Na and Chen, Zhou and Zhou, Shan and Li, Mingkai and Xue, Xiaoyan},
title = {A peptide targeting outer membrane protein A of Acinetobacter baumannii exhibits antibacterial activity by reducing bacterial pathogenicity},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00565-24}
}
EUVIMED